

The Fritsma Factor

YOUR INTERACTIVE HEMOSTASIS RESOURCE

Cheat Sheet—July 2023

Welcome to our July 2023 Cheat Sheet. For our North American participants, happy Canada Day July 1 and happy US Independence Day July 4.

We've returned from the International Society on Thrombosis and Haemostasis [ISTH Congress](#) in Montreal, Quebec, Canada. It was great to connect with Fritsma Factor contributors, Precision BioLogic, Affinity Biologicals, and other colleagues and to make new friends. There are many new developments in the areas of hemophilia therapy and in solving the mysteries of thrombotic microangiopathic anemia [TMA], including thrombotic thrombocytopenic purpura [TTP]. The meeting offered a series of presentations about hemostasis concerns for women, and about care for VWD. Watch Fritsma Factor as we detail ISTH presentation content.

Since Precision BioLogic arranged to refresh Fritsma Factor in the fall of 2022, we've activated over 1000 new members. The refreshed site enables us to accurately identify and block predatory message.

June 2023 Quick Question: Factor VIII Inhibitor Bypass

Caplacizumab, eculizumab, emicizumab, concizumab, who can keep them straight? Which of these is the recently released hemophilia A therapeutic that is overtaking hemophilia A therapy? Or is it Jivi, Eloctate, NovoSeven, Idelveon, or FEIBA?. Click [this link for a summary](#) of our June, 2023 Quick Question.

July, 2023 QQ: Freezing PPP

Our July Quick Question asks, "How long may platelet poor plasma be stored at -20 degrees C?" This reflects our recent series of posts regarding hemostasis specimen management, including our June 21 discussion on [Specimen Transport](#). Many specimen management issues are up for review and will be reflected in a new edition of the CLSI Guideline due in September, labeled H21-A6. We've received several comments on this issue and look forward to more from our participants.

"Coag Conversation," Part Three

On the [BioMedica Diagnostics](#) website, we have posted the third in our three-part "Coag Conversation" series featuring **Dr. Emmanuel Favaloro** speaking on "*The Many Faces of von Willebrand factor; Von Willebrand Factor, ADAMTS13, Malignancy and Beyond.*" The [current post](#) illustrates VWF's association with *arterial thrombosis and cardiovascular disease*. All three posts in this series are now available.

George A. Fritsma MS, MLS

The Fritsma Factor, Your Interactive Hemostasis Resource

george@fritsmafactor.com; www.fritsmafactor.com
